8-K: Amgen Reports Strong Third Quarter 2024 Results Driven by Volume Growth and Horizon Acquisition

Amgen's third quarter 2024 results show a significant increase in revenue and earnings, driven by strong volume growth and the acquisition of Horizon Therapeutics.

Summary

• Amgen's total revenue for the third quarter of 2024 increased by 23% to $8.5 billion compared to the same period in 2023.
• Product sales grew by 24%, with a 29% increase in volume, partially offset by a 2% decrease in net selling price.
• Excluding the Horizon Therapeutics acquisition, product sales grew by 8%, driven by a 12% increase in volume.
• Ten products achieved double-digit sales growth, including Repatha, TEZSPIRE, BLINCYTO, EVENITY, and TAVNEOS.
• Rare disease products contributed $1.2 billion in sales, driven by medicines like TEPEZZA, KRYSTEXXA, UPLIZNA, and TAVNEOS.
• GAAP earnings per share (EPS) increased by 62% to $5.22, while non-GAAP EPS increased by 13% to $5.58.
• Free cash flow for the quarter was $3.3 billion, compared to $2.5 billion in the third quarter of 2023.
• The company has reduced principal debt outstanding by $4.5 billion year-to-date.
• Amgen has updated its full-year 2024 revenue guidance to a range of $33.0 billion to $33.8 billion.
• The company expects full-year GAAP EPS to be between $8.71 and $9.56, and non-GAAP EPS to be between $19.20 and $20.00.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong revenue and earnings growth, driven by volume and the Horizon acquisition. The company is also making good progress with its pipeline and has reduced debt. However, there are some concerns about margin compression and the termination of some clinical trials.

Positives

• Strong revenue growth driven by both volume and the Horizon acquisition.
• Significant increase in earnings per share on both a GAAP and non-GAAP basis.
• Robust free cash flow generation.
• Successful integration of Horizon's rare disease portfolio, contributing significantly to sales.
• Multiple products achieving double-digit sales growth, indicating a strong and diverse portfolio.
• Reduction in debt outstanding, improving the company's financial position.
• Positive clinical trial results for several pipeline products, including rocatinlimab and UPLIZNA.
• Approval of TEPEZZA in Japan, expanding its market reach.
• The company is advancing a broad and deep pipeline that builds on its existing portfolio of medicines.

Negatives

• GAAP operating margin decreased by 5.8 percentage points to 25.1%.
• Non-GAAP operating margin decreased by 2.4 percentage points to 49.6%.
• Some established products experienced sales declines due to volume decreases.
• Otezla sales decreased by 1% year-over-year due to lower net selling price.
• Enbrel sales decreased by 20% year-over-year due to unfavorable changes to estimated sales deductions and lower net selling price.
• MVASI sales decreased by 8% year-over-year due to competition.
• A Phase 2b study of efavaleukin alfa in patients with ulcerative colitis was terminated due to futility.
• A Phase 2 study of fipaxalparant in patients with idiopathic pulmonary fibrosis did not meet its primary or secondary endpoints and development was discontinued.

Risks

• Competition from biosimilars and other products may impact sales.
• Pricing pressure and reimbursement policies could affect revenue.
• Clinical and regulatory developments may impact the success of current and future products.
• Manufacturing difficulties or delays could constrain sales.
• Global economic conditions may affect the company's performance.
• The company's reliance on third-party suppliers and manufacturers poses a risk to supply chains.
• The integration of Horizon may take longer or cost more than expected.
• Cyberattacks or information security breaches could compromise the company's systems and data.
• The company's stock price is volatile and may be affected by a number of events.
• The effects of global climate change and related natural disasters could negatively affect the business.

Future Outlook

Amgen expects full-year 2024 total revenues to be in the range of $33.0 billion to $33.8 billion, GAAP EPS to be between $8.71 and $9.56, and non-GAAP EPS to be between $19.20 and $20.00. Capital expenditures are expected to be approximately $1.3 billion, and share repurchases are not to exceed $500 million.

Management Comments

• Robert A. Bradway, chairman and chief executive officer, stated that strong growth in sales and earnings this quarter reflects the momentum they are building throughout their business.
• He also mentioned that they continue to invest heavily in their rapidly advancing pipeline, with a focus on delivering innovative therapies across their core therapeutic areas.

Industry Context

Amgen's strong performance reflects the ongoing demand for innovative biopharmaceutical products, particularly in areas like oncology, inflammation, and rare diseases. The acquisition of Horizon Therapeutics has significantly boosted Amgen's rare disease portfolio, aligning with the industry trend of companies expanding into specialized therapeutic areas. The company's focus on pipeline development and strategic collaborations positions it well in a competitive market.

Comparison to Industry Standards

• Amgen's 23% revenue growth in Q3 2024 is strong compared to the average growth of large-cap biopharmaceutical companies, which typically see single-digit growth.
• The 29% volume growth in product sales is particularly impressive, indicating strong market demand for Amgen's products.
• The company's non-GAAP EPS growth of 13% is solid, but the decrease in operating margins suggests that integration costs from the Horizon acquisition are impacting profitability.
• Companies like AbbVie and Johnson & Johnson, which also have large portfolios, have seen similar challenges in maintaining margins while integrating acquisitions.
• Amgen's focus on rare diseases through the Horizon acquisition is comparable to companies like Alexion (now part of AstraZeneca) and BioMarin, which have built strong positions in this space.
• The company's pipeline progress, particularly in areas like oncology and inflammation, is consistent with the industry's focus on developing innovative therapies for unmet medical needs.
• The free cash flow generation of $3.3 billion is a positive sign of financial health and is comparable to other large biopharma companies.

Stakeholder Impact

• Shareholders will benefit from the increased revenue, earnings, and free cash flow.
• Employees may see increased job security and opportunities due to the company's growth.
• Customers will have access to a broader range of innovative therapies.
• Suppliers may see increased demand for their products and services.
• Creditors will benefit from the company's improved financial position and reduced debt.

Next Steps

• The company plans to initiate Phase 3 studies for MariTide in multiple indications.
• The company is planning to advance blinatumomab subcutaneous administration to a potentially registration-enabling Phase 2 portion of a study with initiation in H2 2025.
• The company will initiate a Phase 3 study of xaluritamig in post-taxane metastatic castrate resistant prostate cancer in the fourth quarter of 2024.
• The company is planning to initiate Phase 3 studies for TEZSPIRE in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) in H1 2025.
• The company is planning regulatory submissions for UPLIZNA in generalized myasthenia gravis (gMG).
• The company will present data from the AGILE study evaluating KRYSTEXXA at the American College of Rheumatology Convergence (ACR) in November.
• The company will present MITIGATE results at ACR in November.
• Additional key data readouts from the ROCKET Phase 3 program are expected in late 2024 through H2 2025.

Key Dates

Keywords

Amgen, Earnings, Third Quarter, Financial Results, Revenue, EPS, Horizon Therapeutics, Product Sales, Rare Disease, Free Cash Flow, Pipeline, Biopharmaceuticals